News

Filter

1 to 9 of 532 results

US court rules Actavis’ Atelvia patents invalid

US court rules Actavis’ Atelvia patents invalid

05-03-2015

The US District Court for the District of New Jersey has found that Ireland-headquartered Actavis’…

ActavisAnti-Arthritics/RheumaticsAtelviaGenericsLegalPatentsRisedronate SodiumTeva Pharmaceutcal IndustriesUSAWomen's Health

ABPI Rheumatology Initiative report says the UK does not prioritize rheumatoid arthritis enough

ABPI Rheumatology Initiative report says the UK does not prioritize rheumatoid arthritis enough

04-03-2015

Rheumatoid arthritis is not given a high enough priority in the UK, according to a new report from the…

Anti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalResearchSocial IssuesUK

Mundipharma launches monoclonal antibody Remsima in six European markets

26-02-2015

Privately-held UK-based drugmaker Mundipharma International is launching Remsima (infliximab) this month…

Anti-Arthritics/RheumaticsEuropeMarkets & MarketingMundipharmaPharmaceuticalRemsima

Sanofi collaborates with Lead Pharma for autoimmune disease development

Sanofi collaborates with Lead Pharma for autoimmune disease development

18-02-2015

French pharma major Sanofi has entered into a research collaboration and license agreement with privately-held…

Anti-Arthritics/RheumaticsLead PharmaLicensingPharmaceuticalResearchSanofi

Anthera reports positive interim analysis of Phase III blisibimod trial

11-02-2015

US development stage biopharma company Anthera Pharmaceuticals saw its share rocket 25% on Wednesday…

Anthera PharmaceuticalsAnti-Arthritics/RheumaticsBiotechnologyblisibimodResearch

CrystalGenomics signs agreement for Daewoong to commercialize Acelex in Korea

CrystalGenomics signs agreement for Daewoong to commercialize Acelex in Korea

09-02-2015

Korean biopharma company CrystalGenomics has signed a sales and marketing agreement with Daewoong Pharmaceutical…

AcelexAnti-Arthritics/RheumaticsCrystalGenomicsDaewoongLicensingPharmaceutical

Amgen reports its biosimilar ABP 501 meets primary endpoint against adalimumab

Amgen reports its biosimilar ABP 501 meets primary endpoint against adalimumab

04-02-2015

USA-based biotech major Amgen has reported positive top-line data from a Phase III study of its biosimilar…

ABP 501adalimumabAmgenAnti-Arthritics/RheumaticsBiosimilarsHumiraResearchUSA

1 to 9 of 532 results

COMPANY SPOTLIGHT

Menarini

Back to top